Lung Cancer Clinical Trials

• Histologically or cytologically documented non-squamous NSCLC.

• Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.

• Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies.

• Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.

• Known tumour PD-L1 expression status defined as TC ≥ 50%

• At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline

• ECOG performance status of 0 or 1

• Adequate bone marrow reserve and organ function